MarketMoodz
Intuitive Surgical Analysts Boost Forecasts After Strong Q1, Raise 2026 Guidance
Intuitive Surgical beat Q1 2026 estimates with revenue of $2.77B and adjusted EPS of $2.50, nudging its 2026 da Vinci procedure growth higher as adoption of Ion and digital platforms accelerates. The upbeat quarter reinforces a cycle of hospital capital spending on robotic platforms that could lift service and platform revenue in the years ahead.
Key Takeaways
- Q1 2026 revenue of $2.77B vs consensus $2.62B
- Q1 2026 adjusted EPS of $2.50 vs consensus $2.10
- 2026 da Vinci procedures growth guided to 13.5%-15.5% from 13%-15%
- 2026 gross margin guidance of 67.5%-68.5% (vs 67.6% in 2025)
- Shares up ~6.9% to around $482.37; Piper Sandler cut target to $580 and Leerink to $573
People Involved
- Gary S. GuthartChief Executive Officer
- Adam MaederAnalyst, Piper Sandler
- Mike KratkyAnalyst, Leerink Partners
Entities Involved
- Intuitive Surgical Inc (ISRG)Robotics company
MarketMoodz Analysis
The results underscore continued demand for Intuitive Surgical’s robotic platforms (da Vinci and Ion) and digital tools, with a stronger top line and higher 2026 guidance boosting expectations for services and recurring revenue as the installed base expands. A raised 2026 procedure-growth outlook points to a more favorable mix that could lift utilization of service, maintenance and software platforms, supporting a higher-margin trajectory over time.
Investors should view the beat and raised guidance in the context of a multi-year robotics adoption cycle, where hospital capex and procedure volume drive long-run margins. Historically, Intuitive has benefited from an expanding services footprint as its installed base scales; the current guidance implies continued expansion of both installed base and international uptake. Watch for the pace of Ion adoption, digital platform monetization, and commentary on supply chain and pricing discipline on the next earnings call.
Note: one attribution in the coverage appears incorrect—the Benzinga piece cites a quote from a CEO named Dave Rosa. The company’s actual CEO is Gary S. Guthart. While the misattribution does not change the underlying numbers, investors should verify executive commentary against the official earnings release and call for precise context.
Source: Original Article